Posts by Shenglin Mei, PhD
-
Potential Strategy Identified for Treating Bone-Metastatic Clear Cell RCC
Shenglin Mei, PhD, and colleagues used single-cell RNA sequencing to construct a transcriptomic atlas of cells in the microenvironment of human bone-metastatic clear cell renal cell carcinoma and identified a subpopulation of mesenchymal stromal cells as a potential therapeutic target.
-
Primary Prostate Cancer Establishes a Suppressive Immune Microenvironment
Through careful unraveling of the cellular and molecular landscape of prostate cancer, Massachusetts General Hospital researchers observed a highly immune-suppressive tumor microenvironment with a pattern of angiogenic gene expression, findings that will help identify targets amenable to therapeutic interventions.
-
Genetic Signature Predicts Metastasis, Survival in Clear Cell Renal Cell Carcinoma
Shenglin Mei, PhD, Philip J. Saylor, MD, David B. Sykes, MD, PhD, and colleagues found that simultaneous expression of four specific genes predicts survival and metastasis in human clear cell renal cell carcinoma, and they identified other potential therapeutic targets.
Biography
Shenglin Mei, PhD, is an instructor in the Center for Regenerative Medicine at Massachusetts General Hospital and an instructor in Medicine at Harvard Medical School.
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
